Research advances in targeting claudin 18.2 in pancreatic ductal adenocarcinoma treatment

doi:10.3748/wjg.122906

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 45

This Article

(3)

(2)

(0)

(18)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Dec 7, 2026; 32(45): 122906
Published online Dec 7, 2026. doi: 10.3748/wjg.122906

Full Size Figure Download Figure

Figure 2 Targeted treatments for claudin 18. 2-positive tumors. The main forms employ monoclonal antibodies, antibody drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies. CLDN18.2: Claudin 18.2; mAb: Monoclonal antibodies; ADC: Antibody drug conjugates; BsAb: Bispecific antibodies; CAR-T: Chimeric antigen receptor T cell; CD3: Cluster of differentiation 3.

Citation: Wei YH, Zhang SC, Guan BJ, Jian JN, Li CG, Wang ZK, Qu HR, Li ZG, Liu MY, Wang JT. Research advances in targeting claudin 18.2 in pancreatic ductal adenocarcinoma treatment. World J Gastroenterol 2026; 32(45): 122906
URL: https://www.wjgnet.com/1007-9327/full/v32/i45/122906.htm
DOI: https://dx.doi.org/10.3748/wjg.122906

Wei YH, Zhang SC, Guan BJ, Jian JN, Li CG, Wang ZK, Qu HR, Li ZG, Liu MY, Wang JT. Research advances in targeting claudin 18.2 in pancreatic ductal adenocarcinoma treatment. World J Gastroenterol 2026; 32(45): 122906 [DOI: 10.3748/wjg.122906]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.